Mineralys Therapeutics (MLYS) Assets Average (2023 - 2026)

Mineralys Therapeutics has disclosed Assets Average across 4 years of filings, most recently posting $657.3 million for Q1 2026.

• Assets Average for Q1 2026 came in at $657.3 million, up 134.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $657.3 million (up 134.41% YoY), and the FY2025 annual result was $433.9 million, up 89.65% from the prior year.
• Assets Average came in at $657.3 million for Q1 2026 at Mineralys Therapeutics, up from $630.9 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $657.3 million in Q1 2026 to a low of $210.4 million in Q1 2023.
• The 4-year median for Assets Average is $298.8 million (2023), against an average of $354.1 million.
• Across the five-year window, Assets Average dropped 10.4% in 2024 and soared 166.11% in 2025, its largest moves.
• Mineralys Therapeutics' Assets Average stood at $264.6 million in 2023, then dropped by 10.4% to $237.1 million in 2024, then jumped by 166.11% to $630.9 million in 2025, then gained by 4.19% to $657.3 million in 2026.
• The last three Assets Average figures came in at $657.3 million (Q1 2026), $630.9 million (Q4 2025), and $467.8 million (Q3 2025), per Business Quant data.